The probe arises from a complaint by a Teva shareholder alleging price fixing.
Israel's Antitrust Authority has opened an examination of a complaint filed by a Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) shareholder who claimed that Teva subsidiary SLA, which distributes Teva's drugs, also distributed pharmaceutical products of foreign companies, and alleged that it coordinated prices with other companies that distribute their drugs via SLA.
The Antitrust Authority requested certain data relating to this distribution activity, which could give rise to certain suspicions, in order to examine whether it indeed represents a breach of the Restrictive Trade Practices Law.
Teva has been asked to respond to the Authority's approach by Thursday, September 10. Contrary to other reports, the Authority has not encountered any lack of cooperation on Teva's part.
Published by Globes [online], Israel business news - www.globes-online.com - on September 7, 2015
© Copyright of Globes Publisher Itonut (1983) Ltd. 2015
Teva picture: Bloomberg